RxDoctor Payments Data

Alan Fetterman, MD

Geriatric Medicine · Huntington, NYNPI 1891705208

Payments from drug & device makers

$352in general payments, 2019–2025

Across 20 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$107
  • Daiichi Sankyo Inc.$86
  • Amarin Pharma, Inc.$55
  • Braemar Manufacturing, LLC$36
  • Lilly USA, LLC$34
  • Novartis$18
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$32592%
  • Education$288%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk7$107
Daiichi Sankyo Inc.4$86
Amarin Pharma, Inc.4$55
Braemar Manufacturing, LLC1$36
Lilly USA, LLC2$34
Novartis1$18
AstraZeneca1$16

How this compares

$352 in reported general payments places this provider in the 70th percentile of 400 geriatric medicine providers in New York.

See all geriatric medicine providers in New York

Medicare billing

Part B allowed, 2024
$92,358
Medicare patients
301
Services billed
1,162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin56$67,525
TrulicityDulaglutide28$52,715
EliquisApixaban39$46,207
FarxigaDapagliflozin Propanediol24$30,614
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$29,430
RybelsusSemaglutide14$18,696
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$15,336
MounjaroTirzepatide11$10,707
XareltoRivaroxaban12$7,681
MyrbetriqMirabegron15$7,133
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$4,320
Memantine Hcl ErMemantine Hcl16$3,583
Albuterol Sulfate HfaAlbuterol Sulfate103$3,043
Memantine Hcl13$2,686
Atorvastatin Calcium263$2,227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$34$63,42239 claims
AstraZenecaFarxiga$16$30,61424 claims
Novo NordiskRybelsus$107$18,69614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 400 geriatric medicine providers in New York.

Other geriatric medicine in Huntington

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →